Sorry, but this makes clear that you aren’t in science. You should avoid trying to shit on studies if you don’t know how to interpret them. Both of the things you mentioned actually support the existence of a true effect.
First, if the treatment has an effect, you would expect a greater rate of relapse after the treatment is removed, provided that it treats a more final pathway rather than the cause: People in the placebo group have already been relapsing at the typical rate, and people receiving treatment–whose disease has been ramping up behind the dam of a medication preventing it from showing–are then expected to relapse at a higher rate after treatment is removed. The second sixth-month period was after cessation of the curcumin or place; it was a follow-up for treatment-as-usual.
Second, people drop out of a study nonrandomly for two main reasons: side effects and perceived lack of treatment efficacy. The placebo doesn’t have side effects, so when you have a greater rate of dropout in your placebo group, that implies the perceived treatment efficacy was lower. In other words, the worst placebo participants are likely the extra dropouts in that group, and including them would not only provide more degrees of freedom, it would theoretically strengthen the effect.
This is basic clinical trials research knowledge.
Again, I have no skin in the game here. I don’t take curcumin, nor would I ever. I do care about accurate depictions of research. I’m a STEM professor at an R1 with three active federal grants funding my research. The meme is inaccurate.
Sorry, but this makes clear that you aren’t in science. You should avoid trying to shit on studies if you don’t know how to interpret them. Both of the things you mentioned actually support the existence of a true effect.
First, if the treatment has an effect, you would expect a greater rate of relapse after the treatment is removed, provided that it treats a more final pathway rather than the cause: People in the placebo group have already been relapsing at the typical rate, and people receiving treatment–whose disease has been ramping up behind the dam of a medication preventing it from showing–are then expected to relapse at a higher rate after treatment is removed. The second sixth-month period was after cessation of the curcumin or place; it was a follow-up for treatment-as-usual.
Second, people drop out of a study nonrandomly for two main reasons: side effects and perceived lack of treatment efficacy. The placebo doesn’t have side effects, so when you have a greater rate of dropout in your placebo group, that implies the perceived treatment efficacy was lower. In other words, the worst placebo participants are likely the extra dropouts in that group, and including them would not only provide more degrees of freedom, it would theoretically strengthen the effect.
This is basic clinical trials research knowledge.
Again, I have no skin in the game here. I don’t take curcumin, nor would I ever. I do care about accurate depictions of research. I’m a STEM professor at an R1 with three active federal grants funding my research. The meme is inaccurate.